-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1355 TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL

Program: Oral and Poster Abstracts
Session: 602. Myeloid Oncogenesis: Basic: Poster I
Hematology Disease Topics & Pathways:
Research, Fundamental Science, CML, Chronic Myeloid Malignancies, Diseases, Myeloid Malignancies, Biological Processes, Study Population, Human, Pathogenesis, Animal model
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Lu Zhang1*, Xuefeng Wang2,3*, Dongmei Hu4*, Shijie Li4*, Mingshan Sun4*, Qian Liu4*, Huimin Feng4*, Minran Zhou4*, Chen Chunyan, MD4, Huan Zhou2,3* and Sai Ma4*

1Department of Hematology, Qilu Hospital of Shandong University, Jinan, AL, China
2National Drug Clinical Trial Institution, the First Affiliated Hospital of Bengbu Medical University, Bengbu, China
3Key Laboratory of Innovative Drug Pharmaceutical Research and Clinical Evaluation Jointly Established Disciplines in Anhui Province, Hefei, China
4Department of Hematology, Qilu Hospital of Shandong University, Jinan, China

Chronic myeloid leukemia (CML) is a hematopoietic malignancy caused by the BCR-ABL fusion gene. Although tyrosine kinase inhibitors (TKIs) targeting the oncoprotein BCR-ABL have drastically improved the prognosis of patients, TKI resistance has become a major issue, which is caused by mutations in the BCR-ABL kinase domain and other kinase activity-independent mechanisms. Eliminating BCR-ABL at the protein level is a potential therapeutic target for CML. As a posttranslational modification (PTM), SUMOylation plays a critical role in regulating the interaction, stability, and activity of proteins. It is reported that dysregulation of SUMOylation is involved in tumorigenesis. However, the role of SUMOylation in BCR-ABL-induced CML development remains uncertain.

To explore the function of SUMOylation in CML, we treated CML cells with SUMOylation inhibitors, 2-D08 and TAK-981. Treatments inhibited the proliferation and promoted the apoptosis of CML cells. Next, we constructed a mouse model by injecting K562 cells into NOD-SCID mice through the tail vein and treating them with 2-D08. The results showed that SUMOylation was essential for leukemia progression in vivo. Moreover, SUMO1 and SUMO2/3 modifications of BCR-ABL were identified in CML cells.

Liquid chromatography coupled with tandem mass spectrometry showed the potential BCR-ABL interactor, E3 SUMO ligase TRIM28. The association between TRIM28 and BCR-ABL was investigated by immunoprecipitation and confocal microscopy. To further investigate the function of TRIM28 in CML, we generated TRIM28-knockdown and TRIM28-knockout CML cells. TRIM28-knockdown and knockout both inhibited the proliferation and colony formation ability of CML cells.

Next, we determined whether TRIM28 regulated BCR-ABL protein level. We found that TRIM28 knockdown attenuated BCR-ABL protein expression but not mRNA expression. Cycloheximide chase assay showed that TRIM28 knockout promoted BCR-ABL protein degradation. BCR-ABL degradation induced by TRIM28 knockdown or knockout was reversed by autophagy-lysosome inhibitor, chloroquine, and 3-methyladenine (3-MA), but not by the proteasome inhibitor MG132. TRIM28 knockdown inhibited SUMO1 and SUMO2/3 modifications of BCR-ABL, while TRIM28 overexpression promoted SUMO1, SUMO2, and SUMO3 modifications of BCR-ABL. These results revealed that TRIM28 inhibited autophagic degradation by inducing BCR-ABL SUMOylation.

It is reported that p62 was essential for autophagy-lysosomal degradation of BCR-ABL. To elucidate whether TRIM28 impacted p62-mediated autophagic degradation by BCR-ABL SUMOylation, we performed immunoprecipitation and confocal microscopy assay. 2-D08 treatment or TRIM28 knockdown enhanced the interaction between BCR-ABL and p62 compared with the control group. To investigate whether TRIM28 inhibited BCR-ABL protein level to overcome TKI resistance, we used the imatinib-resistant cell line, K562/G01. Treatment with SUMOylation inhibitors, or knockdown TRIM28 expression, inhibited the proliferation of K562/G01 cells.

In conclusion, we demonstrate that upregulated TRIM28 facilitated the SUMOylation of BCR-ABL and subsequently inhibited p62-mediated autophagic degradation, resulting in the progression of CML. Our findings reveal a novel PTM regulating BCR-ABL protein expression and a new therapeutic method for CML.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH